Investor Relations

About

ResApp Health Limited (ASX:RAP) is developing healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease without the need for additional hardware. ResApp has been granted an exclusive license from The University of Queensland for technology that uses sound to diagnose respiratory diseases including pneumonia, bronchitis, chronic obstructive pulmonary disease and asthma. ResApp was formed to commercialise this technology by developing the world’s first clinically-tested, regulatory-approved respiratory diagnostic application for smartphones.

Headquarters

Level 8, 127 Creek St
Brisbane, QLD 4000

Registered Office

Level 24, 44 St Georges Tce
Perth, WA 6000

Board of Directors

Dr Roger Aston – Non-Executive Chairman
Dr Tony Keating – Chief Executive Officer and Managing Director
Brian Leedman – Executive Director and Vice President, Corporate Affairs
Chris Ntoumenopoulos – Non-Executive Director

Listing

Australian Securities Exchange
ASX code: RAP

Share price

Please refer to the ASX website for current share price and history.

Share Registry

Link Market Services Limited
Level 4, Central Park
152 St Georges Terrace
Perth, WA 6000

Investor Relations Contact

Brian Leedman
Executive Director and VP, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

ResApp Logo White

ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 8, 127 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000

© 2016 ResApp Health Limited. All Rights Reserved.

CONTACT US

+61 8 6211 5099
+61 8 9218 8875
General Information
Clinical Studies
Investor Relations

      

LEGAL

Terms of Use
Privacy Policy

ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States.

In the United States, ResAppDx is an investigational device and is not available for sale.